Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at the Society for Melanoma Research (SMR) 2016 Congress

09 November 2016: Oxford, UK - IMCgp100 demonstrates clear early evidence of monotherapy activity in patients with uveal melanoma - Pivotal Phase II clinical study on track to be initiated in first quarter 2017.  Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune diseases, will present positive data from its Phase I clinical monotherapy trial in uveal melanoma (UM) of its lead product, IMCgp100, an ImmTAC (Immune mobilising monoclonal TCRs Against Cancer). These data demonstrate clear early evidence of monotherapy activity of IMCgp100 in patients with uveal melanoma and strengthens the data announced at ASCO 2016. Alexander Shoushtari MD, PhD, Medical Oncologist at Memorial Sloan Kettering Cancer Center, will be giving an oral presentation at the Society for Melanoma Research (SMR) 2016 Congress at the Boston Marriott Copley Place Hotel in Boston, Massachusetts on 9th November, 2016 ...

Read the rest of entry »

Symcel, TiKa Diagnostics and St. George’s University of London Form Partnership to Use calScreener™ in Anti Microbial Susceptibililty Testing

08 November 2016: Spånga, Sweden & London, UK - Symcel, the company behind the revolutionary cell-based assay tool for real-time cellular bioenergetic measurements, calScreener™, has partnered with TiKa Diagnostics and St. George’s University of London, for the use of its microcalorimetry technology in testing mycobacteria and for antimicrobial peptide (AMP) studies. The rapid detection of antimicrobial resistance is now crucial to maximize efforts in controlling the prevalence and spread of drug resistant Mycobacterium tuberculosis (Mtb). Moreover, the development of novel agents, such as AMPs, able to combat superbugs and interfere with biofilm formation, has become a key necessity.

Read the rest of entry »

Science Minister Announces New UK-India Newton Fund Programmes

08 November 2016: London, UK - The UK Science Minister has today () announced a series of research programmes from the Newton Fund worth up to £80 million to address global challenges affecting people in India.

Read the rest of entry »

Oxford Immunotec to Present at the Jefferies 2016 London Healthcare Conference

02 November 2016: Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC , a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016, at 1:20 p.m. GMT (8:20 a.m. ET).

Read the rest of entry »

Wickham Labs to Exhibit at Pharmig 2016

02 November 2016: Gosport, UK - Wickham Laboratories will be on Stand 8 at the 24th Annual Pharmig Conference in the Nottingham Belfry Hotel, November 16th &17th.  Pharmig is a non-profit organisation dedicated to facilitating discussion on the latest research and trends in the field of pharmaceutical microbiology.

Read the rest of entry »

PCI Pharma Services Announces Capacity Expansion to Support Growth

01 November 2016: Philadelphia, USA —  Leading pharmaceutical outsourcing provider PCI Pharma Services (PCI) has announced a capacity expansion program for its commercial contract packaging services at key sites in Philadelphia, PA and Rockford, IL. The announcement follows other recent investments across its integrated global supply network.

Read the rest of entry »

Oxford Immunotec Reports Third Quarter 2016 Financial Results

01 November 2016: Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced third quarter 2016 financial results.

Read the rest of entry »

Electrospinning Company Strengthens the Board

27 October 2016: Harwell, Oxford, UK - The Electrospinning Company has appointed two new non-executive members to its Board of Directors to help develop its strategy and drive its growing business in the regenerative medical device sector. Drummond Paris and Nigel Edwards join Kate Ronayne (STFC Innovations), Malcolm Chapman (lead angel investor) and Ann Kramer (CEO) as well as observer Mark White (Rainbow Seed Fund).

Read the rest of entry »

Jason McDonough of Cello Health Offers His Thoughts on Effective Decision Making in Early Asset Development and Commercialization

25 October 2016: Farnham, UK - How can development teams determine the future value of an asset, with phase 3 data years away? Answering that question requires evaluation of three distinct sources of value: clinical, patient and commercial. Though some consider these value streams independently, the only way to understand how they interact with, and amplify, each other is to review them collectively. Our recommendations on defining the three sources of value, and evaluating them can be found here.

Read the rest of entry »

Genefirst Limited Receives ISO 13485:2003 for Medical Devices

21 October 2016: Abingdon, UK - Genefirst Limited, a molecular diagnostics company working in fields of Infectious Diseases and Personalised medicine reported that it has received ISO 13485:2003 certification for its laboratories based in Abingdon, Oxfordshire.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.